GlassScriptPhysician profile
Mohamed A Sheta
NPI 1457666570
$12,813.60
in general payments reported to CMS, 2019-2025
31 companies · $2,431 in 2025
The $2,431 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $891 · 2021: $949 · 2022: $1,639 · 2023: $2,826 · 2024: $3,309 · 2025: $2,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,528 · Travel and Lodging: $2,528 · Consulting Fee: $2,160 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,528.03 |
| Travel and Lodging | $2,528.20 |
| Consulting Fee | $2,160.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $3,655.08 | 2023-2025 | Prelude Sync Distal, Prelude Ideal, Advance Needle |
| Medtronic, INC. | $2,827.47 | 2021-2025 | Ellipsys Vascular Access System, In.Pact Admiral |
| Horizon Therapeutics Plc | $765.86 | 2021-2023 | |
| Cardinal Health 200 LLC | $751.86 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $568.84 | 2021-2024 | Farxiga, Lokelma |
| W. L. Gore & Associates, INC. | $448.84 | 2019-2022 | |
| Vifor Pharma, INC. | $428.76 | 2021-2023 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $421.73 | 2021-2024 | |
| Amgen INC. | $339.23 | 2022-2025 | Tavneos |
| Travere Therapeutics, INC. | $312.42 | 2022-2025 | Filspari |
| Lemaitre Vascular, INC. | $273.44 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $250.81 | 2022-2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $245.79 | 2022-2024 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $210.72 | 2020-2023 | Jynarque |
| Akebia Therapeutics INC | $179.02 | 2021-2023 | Auryxia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Venturemed Group, INC. | $160.00 | 2023 | Flex Vessel Prep System |
| Opko Pharmaceuticals, LLC | $150.53 | 2022-2023 | Rayaldee |
| Sonavex, INC. | $108.48 | 2023 | |
| Cook Medical LLC | $106.49 | 2020 | |
| Novo Nordisk INC | $97.72 | 2022 | |
| Glaxosmithkline, LLC. | $90.56 | 2022-2023 | Benlysta |
| Bard Peripheral Vascular, INC. | $78.40 | 2019 | |
| Pharmacosmos Therapeutics INC. | $69.51 | 2022-2023 | Monoferric |
| Ani Pharmaceuticals, INC. | $55.96 | 2023 | Purified Cortrophin Gel |
| Outset Medical INC | $50.83 | 2023 | |
| Alexion Pharmaceuticals, INC. | $42.98 | 2022 | |
| Mozarc Medical US LLC | $38.46 | 2024 | Argyle |
| Mallinckrodt Hospital Products INC. | $29.64 | 2023 | Acthar |
| Lilly USA, LLC | $22.35 | 2023 | Mounjaro |
| Alnylam Pharmaceuticals INC. | $20.01 | 2021 | |
| Ethicon US, LLC | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Sheta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.